Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JTT-251 in Pulmonary Arterial Hypertension (RELIEF-PAH)
NCT03789643Phase 2Withdrawn
- Sponsor
- Akros Pharma Inc.
- Start
- Mar 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of JTT-251 in pulmonary arterial hypertension (PAH), sponsored by Akros Pharma Inc.. Planned start Mar 2019; status: withdrawn.
02
Drugs
JTT-251
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03789643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03789643.